Altavo
| Invested since | 2021 |
| Based in | Saxony |
About the company
Altavo is a Dresden based medical technology startup founded in February 2021. Based on non-invasive radar sensing and AI algorithms for speech recognition and synthesis, Altavo is developing prosthetics to improve the rehabilitation of voiceless people, for example after laryngectomy. Compared to existing forms of speech rehabilitation, Altavo’s approach has fundamental advantages in terms voice quality, usability, and complication risks. Altavo is partnering with the Chair of Speech Technology and Cognitive Systems and the Chair of Radio Frequency Engineering at TU Dresden.
Do you want to
know more about this company?
More startups from Life Sciences
faCellitate develops patented polymeric surface coatings for plastic and glassware enabling 3-dimensional cell culture, amongst other uses. Initially, the technology was developed at the BASF research department for polymers. The …
To the complete profileof faCellitate
denovoMATRIX develops and manufactures biomimetic coatings for the cultivation of human stem cells. Our focus is on enabling culture conditions for stem and primary cells closer to the natural conditions …
To the complete profileof denovoMATRIX
oncgnostics develops – based on proprietary epigenetic biomarkers – highly reliable molecular in-vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in oncology.
To the complete profileof oncgnostics
O11 biomedical, a visionary medical technology start-up that emerged as part of BioTex at RWTH Aachen University/ University Hospital Aachen 2022, aims to improve survival rates and quality of life …
To the complete profileof O11 biomedical
Hypros (formerly GWA Hygiene) is committed to reducing the number of hospital infections. For this purpose, the company has developed NosoEx, a modern monitoring system for measuring hand hygiene. The …
To the complete profileof Hypros
Exit
Lipocalyx develops transfection reagents. Our Viromers® are polymers emulating a viral mechanism for cell entry. The company provides reagents and currently establishes services for pharmaceutical applications.
To the complete profileof Lipocalyx